T cells are an important part of the immune system, playing a critical role in the response to infected, foreign or altered cells.
Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.
Team
Insights
Purpose
Commitment
Our People
Companies
News & insights
Information
Legal
News & insights
Information
Legal
Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.
Team
Insights
Purpose
Commitment
Our People
Companies
News & insights
Information
Legal
News & insights
Information
Legal
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $150.63M
Investors 2
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.11.2025 | Series A | $91M | Sofinnova ... |
| 16.11.2023 | Series A | $59.63M | - |
Mentions in press and media 14
| Date | Title | Description |
| 24.03.2026 | Umlaut.bio Secures €3 Million, Pioneers Novel Cancer and Autoimmune Therapies | Umlaut.bio secured €3 million in pre-seed funding. The biotech firm targets cancer and inflammatory diseases. It pioneers first-in-biology small molecules. These molecules inhibit tRNA modification synthesis. This novel mechanism prevents w... |
| 19.03.2026 | German Biotech Kupando Secures €10M for Advanced Immunotherapy Pipeline | Kupando, a prominent German biotech firm, recently announced substantial new financing. The company secured an additional €10 million in Series A funding. This latest capital infusion elevates its total Series A funding to €23 million. The ... |
| 18.03.2026 | Inspired by animal immunity, Germany’s Kupando raises €10 million for cancer therapy | Schönefeld-based Kupando, a biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity and induces trained immunity for use in oncology and infectious diseases, has secured an additional €10 million in Series A f... |
| 20.02.2026 | Cancer and immunology player Umlaut.bio adds funding to reach ~€3 million pre-Seed total | Umlaut.bio, a German/Swiss oncology/immunology BioTech company developing tRNA-modifying small molecules, announced the extension of its pre-Seed financing to ~€3 million through the support of BaseLaunch. This addition not only helps to ac... |
| 18.11.2025 | T-Therapeutics Secures $91 Million to Advance Bispecific Therapies | T-Therapeutics boosts Series A to $91M. New funds will push cancer, autoimmune bispecifics to trials. OpTiMus platform aims to unlock undruggable targets. Investors show strong confidence. **T-Therapeutics Secures $91 Million to Advance Bis... |
| 17.11.2025 | T-Therapeutics Raises $32M in Series A Extension | T-Therapeutics, a Cambridge, UK-based biotechnology company developing new T cell receptor (TCR) therapeutics for cancer and autoimmune disease, raised $32M in Series A extension funding. New investors Tencent and BGF joined the Series A sy... |
| 14.11.2025 | T-Therapeutics: Series A Extended To $91 Million As It Advances First-In-Class Bispecifics Toward The Clinic | T-Therapeutics has expanded its Series A financing to a total of $91 million after securing an additional $32 million from new and existing investors. The Cambridge-based biotechnology company, which develops next-generation T cell receptor... |
| 13.11.2025 | Cambridge startup T-Therapeutics secures €27.5 million to improve how the immune system targets disease | T-Therapeutics, a British BioTech company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announced the successful expansion of its Series A financing, raising a further €27.5 million (... |
| 04.08.2025 | Cambridge Innovation Capital: £100+ Million Committed To University Spin-Outs | Cambridge Innovation Capital (CIC) is investing at least £100 million in spinouts from the University of Cambridge, leveraging the commercial potential of its research in science and technology. This initiative supports the university’s pla... |
| 19.03.2024 | The World’s Most Innovative Companies of 2024 | - |
Show more